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Anticonvulsant actions of dynorphin were proposed since
more than 2 decades, however till now, we do not have
information on the functions of endogenous dynorphin.
Thus, we investigated prodynorphin knockout (KO) mice
in different models of seizures and epilepsy. Seizure
threshold was investigated by tail-vein infusion of 100 μg
pentylenetetrazole (PTZ)/ml at a rate of 100 μl/min until
mice displayed generalized clonic seizures. Wild-type
mice showed clonic seizures at 39.2 ± 1.88 (mean ± SEM;
n = 5) mg PTZ/kg body weight. KOs displayed a signifi-
cantly reduced seizure threshold of 32.7 ± 1.17 (n = 6) mg
PTZ/kg. This phenotype could be rescued entirely by the κ
opioid receptor specific agonist U-50488, but not the μ
opioid receptor specific agonist DAMGO. The δ opioid
receptor specific agonist SNC80 decreased seizure thresh-
old in both genotypes. Pre-treatment with the κ-selective
antagonist GNTI completely blocked the rescue effect of
U-50488. After injection of kainic acid into stratum radia-
tum of CA1 of the dorsal hippocampus, KO mice dis-
played increased neuronal loss along the rostro-caudal
axis of the ipsi- and partially the contralateral hippocam-
pus at early time points after treatment. Thus, marked
neurodegeneration was seen already 1 week after treat-
ment in KO mice. The differences faded with time, being
almost gone 5 weeks after kainate. Our data clearly indi-
cate that endogenous prodynorphin derived peptides have
anticonvulsant and neuroprotective properties.
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